These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 17952738)

  • 1. Tyrosine kinase inhibitors in pediatric malignancies.
    Skolnik JM; Adamson PC
    Cancer Invest; 2007; 25(7):606-12. PubMed ID: 17952738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of tyrosine kinase inhibitors in cancer therapy.
    Arora A; Scholar EM
    J Pharmacol Exp Ther; 2005 Dec; 315(3):971-9. PubMed ID: 16002463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments.
    Steeghs N; Nortier JW; Gelderblom H
    Ann Surg Oncol; 2007 Feb; 14(2):942-53. PubMed ID: 17103252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of signal transduction protein kinases as targets for cancer therapy.
    Mikalsen T; Gerits N; Moens U
    Biotechnol Annu Rev; 2006; 12():153-223. PubMed ID: 17045195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Protein tyrosine kinase inhibitors in cancer therapy].
    Boutayeb S; Zakkouri FZ; Aitelhaj M; Mesmoudi M; Boutayeb A; Boutayeb W; Mrabti H; Errihani H
    Pathol Biol (Paris); 2012 Aug; 60(4):229-33. PubMed ID: 22743095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Imatinib--a new perspective in the treatment of tumors].
    Klener P; Klamová H
    Cas Lek Cesk; 2004; 143(9):579-80, 582-3. PubMed ID: 15532894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The biology of signal transduction inhibition: basic science to novel therapies.
    Griffin J
    Semin Oncol; 2001 Oct; 28(5 Suppl 17):3-8. PubMed ID: 11740801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New tyrosine kinase inhibitors in chronic myeloid leukemia.
    Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
    Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Signal transduction therapy in haematological malignancies: identification and targeting of tyrosine kinases.
    Chase A; Cross NC
    Clin Sci (Lond); 2006 Oct; 111(4):233-49. PubMed ID: 16961463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
    Walz C; Sattler M
    Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias.
    Kantarjian HM; Talpaz M
    Semin Oncol; 2001 Oct; 28(5 Suppl 17):9-18. PubMed ID: 11740802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel approaches to the development of tyrosine kinase inhibitors and their role in the fight against cancer.
    Zámečníkova A
    Expert Opin Drug Discov; 2014 Jan; 9(1):77-92. PubMed ID: 24294890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to tyrosine kinase inhibitors: calling on extra forces.
    Cools J; Maertens C; Marynen P
    Drug Resist Updat; 2005 Jun; 8(3):119-29. PubMed ID: 15869901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquired resistance to tyrosine kinase inhibitors during cancer therapy.
    Engelman JA; Settleman J
    Curr Opin Genet Dev; 2008 Feb; 18(1):73-9. PubMed ID: 18325754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiotoxicity induced by tyrosine kinase inhibitors.
    Orphanos GS; Ioannidis GN; Ardavanis AG
    Acta Oncol; 2009; 48(7):964-70. PubMed ID: 19734999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance.
    Levitzki A
    Annu Rev Pharmacol Toxicol; 2013; 53():161-85. PubMed ID: 23043437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flying under the radar: the new wave of BCR-ABL inhibitors.
    Quintás-Cardama A; Kantarjian H; Cortes J
    Nat Rev Drug Discov; 2007 Oct; 6(10):834-48. PubMed ID: 17853901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Important therapeutic targets in chronic myelogenous leukemia.
    Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
    Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Inhibition of the VEGF receptor system with tyrosine kinase inhibitors. Angiogenesis inhibition in oncology].
    Mross K
    Pharm Unserer Zeit; 2008; 37(5):404-15. PubMed ID: 18729270
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.